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Abstract Tumor associated monocytes/macrophages
(MO/MA) are known contributors to the immune-inflam-
matory cell environment of advanced epithelial ovarian
carcinoma (EOC). The secreted proteome of ascitic MO/
MA was examined as an aid to the discovery of novel
proteins in EOC that are likely to have biological relevance
in the inflammatory pathways of EOC. Ascitic fluid MO/
MA were isolated from EOC patients, grown short-term in
serum-free media. MO/MA supernatants were analyzed for
secreted proteins by HPLC fractionation followed by LC-
tandem mass spectrometric analysis. The 14-3-3 zeta
adaptor protein was identified in supernatants of three of
three EOC patients but not in supernatants of buffy coat
monocytes isolated from normal donors or the established
monocyte cell line THP1. Moreover, 14-3-3 zeta was
identified in ascitic fluids in eight of eight chemotherapy-
naı¨ve patients by both immunoblot and mass spectrometric
analysis. Immunofluorescent staining for 14-3-3 zeta
demonstrated expression of the protein on ascitic and
peritumoral macrophages in EOC patients. 14-3-3 zeta was
also expressed on endothelial cells in the peritumoral
stroma and partially on tumor cells. Uptake of 14-3-3 zeta
was observed in EOC cell lines co-cultured with the
recombinant protein expressed in E. coli. It is demonstrated
for the first time that the important adaptor protein 14-3-3
zeta is common to the secretome of ascitic MO/MA and the
ascites of advanced EOC patients.
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Introduction
As currently practiced, the treatment of stage III or IV
epithelial ovarian carcinoma (EOC) results in a 5-year
survival rate of only 25–30%. This poor outcome contrasts
with a 10-year survival rate of 90% for stage I patients,
where peritoneal and serosal tumor involvement is absent.
Clearly, morbidity and mortality in EOC are related to
peritoneal and serosal tumor involvement. The peritoneum
protects the integrity of intra-abdominal organs and can
also facilitate infiltration of inflammatory cells to sites of
infection or injury, thus localizing pathologic effects.
Examination of the peritoneum and ascites of patients with
advanced EOC reveals high numbers of inflammatory cells
comprised largely of monocytes/macrophages (MO/MA)
that express markers of activation [13]. The importance of
MO/MA in disease progression of EOC is supported by
several studies [1, 6] and as reviewed previously [7]. For
example, elevated blood levels of the MA-differentiating
cytokine macrophage colony-stimulating factor 1 (MCSF),
which is also produced by MO/MA, correlates both with
disease progression and with poor survival [1]. Further, the
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proangiogenic factors interleukin-8 (IL8) and vascular
endothelial growth factor (VEGF), which are produced by
peritoneal and ascitic MO/MA and by EOC tumor cells and
stromal cells, have been shown to correlate with poor
survival in EOC patients [6]. Most of the proteins with
potential protumor activity which are secreted by tumor
associated MO/MA have been identified using antibody
based methods. There is also a need to identify other lesser
known proteins which may have an important role in tumor
progression and metastasis.
The MO derived THP1 cell line was employed as a first
step in the examination of the secretome of MO/MA. This
was followed by an examination of the secretome of
purified MO/MA isolated from the ascitic fluid of EOC
patients. Supernatants from buffy coat derived MO/MA
were compared to those of ascitic MO/MA. A single
protein, 14-3-3 zeta, was identified in each of three
supernatants of EOC ascitic MO/MA and also detected in
ascites of all eight patients examined. An antibody specific
to this protein was generated and costaining experiments
demonstrated 14-3-3 zeta expression on ascitic MO/MA,
the peritoneum, tumor stroma, endothelial cells, and vari-
ably on tumor cells.
Materials and methods
Isolation of MO/MA from ascitic fluid and collection
of supernatant
Human tissues were obtained under University of Texas MD
Anderson Cancer Center IRB approved protocol, and writ-
ten informed consent obtained from all patients. Ascitic MO/
MA from EOC patients were isolated as previously descri-
bed [5, 13]. We used a sequential procedure that involved a
Ficoll-Hypaque density cushion followed by adherence for
1 h. In the CD163 MO/MA subset experiment a MO Isola-
tion Kit and a MACS separator (Miltenyi Biotec, Auburn,
CA) were utilized according to the manufacturer’s instruc-
tions. Cells were labeled with a hapten-antibody cocktail
(containing monoclonal hapten-conjugated CD3, CD7,
CD19, CD45RA, CD56 and anti-IgE antibodies) and
MACS Anti-Hapten Microbeads, washed with buffer (PBS
with 0.5% human albumin and 1 mM EDTA), and then run
through a column placed in a MACS magnetic separator.
The unattached MO/MA were collected, while the mag-
netically labeled T cells, B cells, NK cells, DC, and
basophils remained attached to the column. When large
numbers of tumor cells were present, anti-HEA (EpCAM)
microbeads were added to the column. Purified MO/MA
were then placed in a 6-well plate and cultured in Krebs-
Hensleit buffer. Supernatants were collected after 2–9 days
of incubation, based on optimum viability, and in CD163
experiments at 0, 24, and 48 h.
Oligofractionation of secreted proteins from the ascitic
MO/MA of EOC patients
For secreted proteome analysis, 200 ll of supernatant was
taken from each sample and fractionated by HPLC (Hew-
lett Packard 1090) using a reversed phase column (Vydac
C4, 1 9 250 mm). After extensively washing the column
to eliminate salts and other small molecules mostly derived
from media, the proteins were eluted with an increasing
gradient of acetonitrile and collected into three 10 min
fractions. The HPLC gradient was set as follows: 10%
solvent B (70% acetonitrile/water, 0.091% TFA), 90%
solvent A (2% acetonitrile/water, 0.1% TFA) from 0–
30 min; 50% B, 50% A at 50 min; 90% B, 10% A at
60 min and 90% B, 10% A until 70 min. After trypsin
digestion, the three fractions were subjected to mass
spectrometric analysis. This HPLC separation achieves the
cleanest sample possible, while still permitting high sen-
sitivity mass spectrometric analysis.
Mass spectrometric analysis
LC-tandem mass spectrometric (LC-MS/MS) analysis of
the secreted proteome was performed using an ion-trap
mass spectrometer (Thermo Electron LTQ) connected with
a reversed phase column (LC-Packings C18 PepMap,
75 lm 9 150 mm). Mascot was used to search the mass
spectra against NCBI databases. Proteins that were mat-
ched with reasonable mass spectra are listed (Table 1).
Anti-14-3-3 zeta antibodies
Since no commercial antibody specific to 14-3-3 zeta was
available, due to its high homology with other isoforms, a
synthetic peptide was designed based on the sequence
analysis of all seven 14-3-3 isoforms (Fig. 1) and the
crystal structure of 14-3-3 zeta [8]. A peptide with N-
terminal cystein was synthesized (CEKFLIPNASQAE,
residues 102–113), conjugated to KLH, and used to
immunize rabbits. Anti-peptide antibodies were purified by
affinity chromatography over a peptide column (GenScript,
Piscataway, NJ).
Detection of secreted 14-3-3 zeta in ascitic fluid
Ten microliters of ascitic fluid isolated from patients with
ovarian cancer was first cleaned by immunodepletion col-
umn chromatography to remove serum albumin and 5 other
abundant proteins (MARS, Agilent technologies, Palo Alto,
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CA). One-twentieth of the cleaned ascitic fluid was used for
immunoblot analysis with 14-3-3 zeta antibodies (Santa
Cruz SC-1019 with greater specificity for zeta and to a lesser
extent beta and sigma). The silver stained gel area corre-
sponding to the band in immunoblot analysis was excised
and in-gel digested using trypsin. The extracted peptides
were analyzed with LC-MS/MS mass spectrometry.
Targeted acquisition in LC-MS/MS
To increase sensitivity, we selectively acquired ms/ms
spectra corresponding to the doubly charged states of seven
14-3-3 peptides. Selection of these peptides was based
on analyses of digested recombinant material and
consideration of the sequence. The mass spectrometer was
programmed to sequentially acquire 6 ms/ms spectra
repeatedly through the run, with m/z corresponding to the
doubly charged peptides. The isolation width was 4 m/z
and 2 micro-scans were acquired per spectrum. Normalized
collision energy was set to 35. Activation Q was 0.250 with
an activation time of 30 ms.
Construction of N-terminal FLAG-tagged 14-3-3 zeta
protein
cDNA for 14-3-3 zeta (accession number BC003623) was
obtained from Open Biosystems (www.openbiosystems.
com). The sequence was inserted into the pT7-FLAG-1
Table 1 Secreted proteomes of MO/MA isolated from the ascites of patients with EOC
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bacterial expression vector (www.sigmaaldrich.com). Pro-
tein was expressed in E. coli BL21 cells, purified with
Anti-FLAG Agarose M2 (Sigma-Aldrich, St. Louis, Mis-
souri), and eluted with FLAG peptide (100 lg/ml) in
50 mM Tris-HCl with 150 mM NaCl, pH7.4. The amino
acid sequence of the N-terminal through the 14-3-3 zeta
start Methionine is ‘‘MDYKDDDDKLAAAM’’ (FLAG
epitope sequence is underlined).
Indirect immunofluorescence staining and confocal
microscopy
Antibody costaining of ascitic cells, tumor and peritoneum
tissues was performed by methods and with reagents that we
have described previously utilizing cell localization primary
antibodies for cytokeratin (tumor cells), CD163(MO/MA),
CD31(endothelial cells), and CD3 (T-cells) [4].
Table 1 continued
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Established ovarian tumor cell lines CaOV3 and
MDA2774, 100,000–50,000 cells per well, were seeded
into 8 chamber polystyrene vessel tissue culture treated
glass slides (Becton, Franklin Lakes, NJ) and incubated for
24 h at 5% CO2 incubator. Cultured cells were washed
twice with warmed RPMI 1640 only, then replaced with
fresh media without and with FLAG-tagged 14-3-3 zeta in
concentration of 2 lg/well at 5, 30, 60 and 120 min. After
exposure to FLAG-tagged protein, cells were washed three
times with PBS without Ca++ and Mg++, fixed immedi-
ately with cold (-20C) methanol for 5 min and washed
three times with PBS. Permeabilization of cells were
applied by using 0.5% Triton X-100 for 15 min and
nonspecific binding proteins were blocked by adding 5%
normal goat serum for 30 min. The primary antibody, anti-
FLAG M2 monoclonal antibody IgG1, 20 lg/ml (Sigma-
Aldrich, St. Louis, Missouri) was incubated on fixed cells
for overnight at 4C and reacted with Cy2-conjugated
(green) AffiniPure goat anti-mouse IgG, Fcg subclass
1- specific (Jackson ImmunoResearch Laboratories, West
Grove, PA). The nuclei of cells were stained with
TO-PRO3, 1/2,000 dilution (Molecular Probes, Eugene
OR) for 15 min; washed and mounted with Slow-Fade
Gold anti-fade reagent (Molecular Probes, Eugene OR).
Cells were viewed with an Olympus FV500 laser scanning
confocal microscope; images were captured at 2009
magnification and zoomed 5X using Fluoview software
program Version 4.3. The positive and negative cells were
read in the same fluorescence channel with the same
settings.
Results
Secreted proteome of THP1 cells
We first tested the feasibility of isolating the secreted
proteome of a pure population of cells utilizing THP1 [12],
an established cell line of MO-myeloid lineage. THP1 cells
were grown in serum-free medium for 7 days. The secreted
proteins were separated by HPLC and then analyzed by
either Edman degradation or by LC-tandem mass spectro-
metric analysis after trypsin digestion. The major proteins
identified in the secreted proteome are lysozyme, chitinase
3-like 1 (YKL-40), proteinase 3, azurocidin, cathepsin G,
beta-2 microglobulin, cystatin C, desmoglein-1, secretory
granule proteoglycan core protein, adenyl cyclase-associ-
ated protein (CAP1), junction plakoglobin, plakophilin1,
moesin, palmitoyl-protein thioesterase, alpha-enolase, and
prostaglandin-H2 D-isomerase (unpublished results). Azu-
rocidin, and cathepsin G are known to have chemotactic
activity [2]. Lysozyme and proteinase 3 are known to be
involved in inflammation [2]. The secreted proteome
analysis of THP1 resulted in identification of proteins
functionally related to monocyte activity.
Secreted proteomes of MO/MA isolated from ascites
of patients with EOC
Our secreted proteome study of the THP1 cell line dem-
onstrated the feasibility of identifying a variety of
functionally relevant proteins produced by a purified cell
population. We utilized the same approach to analyze the
secreted proteome of ascitic fluid MO/MA, which we iso-
lated from patients with EOC using a Ficoll-Hypaque
density cushion followed by adherence. Similarly, we
Table 1 continued
The peptides identified in the secreted proteome analysis are sum-
marized in different colors. Proteins found in both the control (buffy
coat) and patients are in blue. Those unique to control are in green.
Proteins found in either patients or control, but with no significant
pattern, are coded in black. A protein found in all patients but not in
the buffy coat control is coded in red. In mass spectrometry analysis, a
higher score indicates higher confidence of identification. The number
under the peptide column indicates the number of peptides matched in
a sequence database search. MCSF(+) indicates MO/MA incubated
with MCSF, and MCSF(-) indicates those incubated without MCSF.
The Mascot scores of proteins identified in multiple HPLC fractions
were combined and listed as the total score (indicated with an
asterisk)
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analyzed the secreted proteome of buffy coat specimens,
isolated using an MO isolation kit and MACS separator.
Ascitic MO/MA were selected because they are the major
representative of cell populations that contribute to the
EOC inflammatory microenvironment and because of the
facility with which they can be isolated and studied. MO/
MA isolated from ascitic fluid as adherent cells provided
more than 90% purity and showed 99% viability. The
purified MO/MA were grown in serum-free medium, either
with or without MCSF. However, inclusion of MCSF in the
media had no apparent influence on viability of the isolated
MO/MA. Non-adherent cells were removed from the cul-
tures after 1–2 h. MO/MA supernatant were collected
between 2 and 9 days from viable adherent MO/MA cul-
tures. A suitable ascitic MO/MA control was unavailable
from patients with benign disease, so column purified
buffy-coat MO/MA isolated from normal donors were used
for comparison (Table 1). Two hundred microliters of the
ascitic MO/MA supernatants were separated by reversed-
phase HPLC, digested with trypsin, and analyzed by LC-
tandem mass spectrometry. Using this strategy, we identi-
fied 30–60 proteins from the supernatants of ascitic MO/
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The peptide used to generate antibody is shown in box.
Fig. 1 Alignment of 14-3-3
zeta with its other isoforms and
the peptides identified by mass
spectrometry analysis. Multiple
sequence alignment was
performed using the online
alignment tool MAFFT (ver.
5.667). The peptides identified
in secreted proteome analysis by
mass spectrometry are
highlighted either in boldface or
underline. The peptides in
boldface are sequences unique
to 14-3-3 zeta which were
identified in the secretome
analysis
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MA. For example, from one patient’s sample we identified
53 total proteins that were divided into 4 groups: 36 pro-
teins common to buffy coat; 16 proteins found only in one
or two patients but not in all patients; and one common
protein, 14-3-3 zeta, found in ascitic MO/MA supernatants
from 3 of 3 EOC patients but not in supernatants of buffy
coat cells (Table 1).
The 14-3-3 zeta unique peptide SVTEQGAELSNEER
(residues 28–41) was identified in all 3 patients. The zeta
unique peptide YLAEVAAGDDKK (residues 128–139)
was identified in patients #290 and #288. The zeta unique
peptide GIVDQSQQAYQEAFEISK (residues 140–157)
and TAFDEAIAELDTLSEESYK (residues 194–212) were
also identified in patient #290.
Further study was therefore focused on the 14-3-3 zeta
protein. We also analyzed secreted proteins from
CD163 + and CD163- cells using the MACS separator
columns as described above. Secreted proteomes were
analyzed in the same manner after 24 and 48 h incubations
(Supplementary Table S1).
Immunoblot and mass spectrometric analysis of 14-3-3
zeta confirmed its secretion into the ascites
of all patients with ovarian cancer
Ascitic fluid utilized in this study was obtained from 8
patients with advanced, untreated EOC of the most com-
mon histology, which is serous carcinoma stage 3 (5
patients) or stage 4 (3 patients). 14-3-3 zeta was identified
in ascitic fluid from all 8 patients (Fig. 2). LC-MS/MS
analysis of the gel bands corresponding to the bands in
immunoblot analysis confirmed presence of 14-3-3 zeta
protein by detecting peptides with sequences unique to the
zeta isoform. The 14-3-3 zeta unique peptide SVTEQ-
GAELSNEER (residues 28–41) was identified in all 8
samples. The zeta unique peptide GIVDQSQQAYQEA
FEISK (residues 140–157) was also identified in samples 5,
6, 7, and 8. The zeta unique peptide YLAEVAAGDDKK
(residues 128–139) was identified in sample 6.
Immunofluorescence studies
Since 14-3-3 zeta was first isolated from ascitic MO/MA,
we stained a sample of unseparated ascitic cells and
demonstrated costaining of CD163 + MO/MA for 14-3-3
zeta using the antibody we had developed with specificity
for the 14-3-3 zeta analogue (Fig. 3a). Also seen are
CD163- cells, of similar size and morphology to the
CD163 + cells, which were also positive for 14-3-3 zeta.
In contrast, large ascitic mesothelial cells (CK+) were
negative or only weakly positive for 14-3-3 zeta.
Approximately 50% of EOC associated MO/MA express
the CD163 phenotype (1). Costaining of ascitic MO/MA
for 14-3-3 zeta was also confirmed on a purified ascitic
MO/MA (data not shown). In Fig. 3b, 14-3-3 zeta
antibody staining of a cryostat section, obtained from a
peritoneal biopsy from a patient with benign disease,
primarily stains the peritoneal mesothelial (CK+) surface
cells but not the resident CD163 + MO/MA. Further,
specificity for the 14-3-3 zeta isoform on the surface
mesothelial cells was confirmed by blocking the binding
of the antibody with an epitope matching peptide.
We next utilized our antibody to describe 14-3-3 zeta’s
expression on EOC tumor and on peritoneal tissue speci-
mens utilizing fluorescence costaining. We have previously
shown that MO/MA represent a major leukocyte popula-
tion in the peritoneum surrounding the tumor of EOC
patients and there are large accumulations of MO/MA deep
to the surface mesothelium [13]. Thirteen tumor specimens
from representative EOC specimens were examined in
detail (Fig. 4; Table 2). These experiments demonstrated
that tumor cells (CK +), MO/MA (CD163 +), and endo-
thelial cells (CD31 +), as well as other stromal cells,
expressed the 14-3-3 zeta protein, though at differing fre-
quency and intensity. Staining for 14-3-3 zeta protein was
strongest on stromal cells and on MO/MA, particularly the
cells found close to and within clumps of tumor cells in 10
of 13 samples. There was also positive costaining of CD31
endothelial cells for 14-3-3 zeta. Tumor cells that were
positive for 14-3-3 zeta showed nuclear or cytoplasmic
staining, and in 7 of 13 samples, cytoplasmic staining of
tumor cells was negative, weak, or only focal (Table 2).
We also found that 14-3-3 zeta was expressed on
CD163 + MO/MA in peritoneum obtained from tumor
free sites of 3 patients with EOC and on mixed Mullerian
tumor of the ovary, but only focally on the CD3 + T-
lymphocyte population (data not shown).
Co-culture experiment of 14-3-3 zeta with EOC
cell lines
A recombinant FLAG-tagged 14-3-3 zeta was co-cultured
with two EOC cell lines, CaOV3 positive cell line and
Fig. 2 Immunoblot and mass spectrometric analysis confirmed of 14-
3-3 zeta in the ascites of 8 patients with EOC. The amount of ascitic
fluid used to detect 14-3-3 zeta for immunoblot analysis was 2.5 ll
for lanes 1–4, 1.3 ll for lanes 5 and 6, and 0.42 ll for lanes 7 and 8.
All of the bands were confirmed by identifying peptides unique to the
zeta isoform using LC-MS/MS analysis
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MDA2774 cell line, to see whether the protein is taken up
by EOC cells. In comparison to other EOC tumor lines
tested these two cell lines did not have detectable 14-3-3
zeta by immunofluorescence (data not shown). Positive
fluorescence specifically generated by anti-FLAG antibody
were observed on CaOV3 positive cells and MDA2774
cells after 120 and 60 min incubations with FLAG-tagged
14-3-3-zeta, respectively (Fig. 5).
Fig. 3 a Immunofluorescence experiments revealed costaining of 14-
3-3 zeta on CD163 + peritoneal MO/MA. Shown is triple indirect
immunofluorescence costaining of cytospin preparation of ascitic
peritoneal cells from ID294. Peritoneal cells were fixed with 4%
paraformaldehyde and stained with antibodies for the following
antigens; cytokeratin (CK) = blue, 14-3-3 zeta = red and
CD163 = green reacted with Cy2, Cy3, and Cy5 conjugated affin-
ipure antibodies corresponding to the isotype of primary antibody.
Coexpression of 14-3-3 zeta on ascitic CD163 + cells is shown in
yellow. The right upper panel shows Wright’s stain of ascitic cells
from the same sample (630 magnification). Images were made at
4009 magnification and 49 zoom using Fluoview software version
4.3. b. Immunofluorescence staining of normal peritoneum for14-3-3
zeta identifies with surface mesothelium primarily. Expression of
inflammatory MA cells marker CD163 (green), 14-3-3 zeta (red), and
keratin/CK (blue) is shown on cryosections of benign peritoneum
(ID283). Images from ID283 showed scant presence of
CD163 + inflammatory cells. 14-3-3 staining is mainly identified
with surface mesothelium. Specificity for 14-3-3 zeta expression was
demonstrated by blocking with peptide, designated ‘‘BP.’’ Red
staining indicates the presence of 14-3-3 zeta. Top two panels lack
blocking peptide. Lower two panels show absence or only weak
staining of 14-3-3 zeta in presence of blocking peptide (0.173 mM
peptide solution). The magenta staining reaction indicates costaining
of mesothelial cells (CK +) with 14-3-3 zeta. H&E and DIC images
provide anatomic localization for the positively stained cells shown in
laser confocal microscopy. Magnification for confocal is 4009
254 Cancer Immunol Immunother (2009) 58:247–258
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Discussion
In previous studies, we showed that the peritoneal tissues
from EOC patients have an inflammatory profile that is
consistent with MO/MA activation [14] by both differential
microarray analysis [14] and by in situ cellular staining
[4, 13]. In previous studies [5, 9] we have also shown that
ascitic MO/MA are inhibitory to T cell proliferation, or
have lost the capacity to mediate opsonization and anti-
body-dependent cell-mediated cytoxicity [5], while they
continue to produce cytokines and chemokines that could
support the tumor. Although previous studies have
Fig. 4 Immunfluorescence




(upper panel), and endometrioid
cancer, ID299 (lower panel),
utilizing three antibody
combinations reactive against
a cytokeratin (CK) (blue)/14-3-
3 zeta (red)/CD163 (green);
b cytokeratin (green)/14-3-3
zeta (red)/CD31 (blue). Strong
costaining of CD163 + MA,
14-3-3 zeta also strongly stains
other cells in stroma but
CK + tumor cells only focally.
H&E preparations correspond to
identical or similar structures
shown in laser confocal
microscopy panels. Results
described in text (4009
magnification)
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Table 2 14-3-3 zeta
localization on EOC and
environmental cells of
13 patients
Quantitation: focal (F) \ 5%;
weak (W) 6–33%; moderate
(M) [ 33–66%; strong
(S) [ 66%
a Mullerian origin
b Stronger in proximity to
tumor. NT not tested
c 14-3-3 zeta isolated from MO/
MA supernatants of this patient
ID# Histologic type Stage/
grade





243 Mucinous 3/Mod S S W(scanty) S NT
256 Endometrioid 2/High W W S S NT
279 Undifferentiateda 4/High Neg Neg S Neg M
287 Serousc 4/High M Neg Wb W NT
291 Serous 3/High S S Wb M NT
293 Mixed Mullerian 3/High Neg F W M S
294 Serous 3/High S S F(scanty) M NT
296 Serous and
endometrioid
3/High F S Mb S NT
297 Serous and
endometrioid
3/High F M Wb S NT
298 Serous 3/High Neg Neg Mb S NT
299 Endometrioid 3/High Neg F Sb S S
300 Serous 3/High S M Sb S S
301 Serous 4/High Neg F S S NT
Fig. 5 14-3-3 zeta uptake by
cutured EOC cells. Cell lines
CaOV3 and MDA 2774 were
cultured for 24 h at 5% CO2,
then treated with 2 lg per well
of FLAG-tagged 14-3-3 zeta or
untreated cells as negative
controls for different periods of
time including 5, 30, 60 and
120 min. CaOV3 positive cells
are seen at 120 min incubation,
while MDA2774 showed
positive fluorescence at 60 min
incubation of protein with
FLAG-tag
256 Cancer Immunol Immunother (2009) 58:247–258
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described a number of proteins secreted by MO/MA, they
have generally employed antibody-based methods, using
commercially available cytokine and chemokine detection
kits. Here we employed an unbiased approach, utilizing
mass spectrometry with the highest available sensitivity.
Although not as sensitive as ELISA, it has enabled the
discovery of a broad range of proteins secreted by a single
population of cells. In particular, we were able to identify
an adaptor protein, 14-3-3 zeta, which was commonly
produced and secreted by three of three purified ascitic
MO/MA samples. Furthermore, we produced a zeta spe-
cific antibody and identified 14-3-3 zeta in MO/MA that
were detected in peritoneum and tumor of EOC patients.
Other cells that expressed 14-3-3 zeta included tumor,
either nuclear or cytoplasmic, stroma, and endothelial cells.
14-3-3 zeta was also identified in all eight of the EOC
ascites specimens from chemotherapy-naı¨ve patients. 14-3-
3 zeta is also expressed in other normal cells such as the
peritoneum as demonstrated in Fig. 3b. This is not sur-
prising if it is considered that the peritoneum is an organ
that as a protective function.
14-3-3 zeta is an important regulatory protein in intra-
cellular signaling pathways and is known to interact with
more than 100 cellular proteins, including oncogene and
protooncogene products. Crystal structures have shown
that 14-3-3 zeta forms a dimer and binds to proteins with
tandem repeats of phosphoserine motifs [16]. It has been
reported that 14-3-3 zeta blocks apoptosis by inhibiting the
activation of p38 mitogen-activated protein kinase
(MAPK) [15] and plays a critical role as an anti-apoptotic
factor in cells. It is also reported that MAPK-activated
protein kinase 2 (MAPKAPK2), a p38 MAPK-dependent
inflammatory response mediator, regulates dimerization of
14-3-3 zeta through phosphorylation of Ser-58. In its
phosphorylated form, 14-3-3 zeta appears unable to
dimerize or bind to Raf-1 [10]. 14-3-3 zeta is also reported
to interact with beta-catenin, enhance or inhibit beta-cate-
nin-dependent transcription, facilitate activation of beta-
catenin through Akt, and possibly be involved in stem cell
development [11]. Recently, it was reported that MO/MA
infected in-vitro with human immunodeficiency virus type-
1 also secrete 14-3-3 zeta/delta [3].
Due to 14-3-3 zeta’s many regulatory interactions, and
since MAPK participates in LPS-induced proinflammatory
cytokine production in macrophages and in other inflam-
matory responses its expression in ascites and ascitic cells
was investigated. Since 14-3-3 zeta was the only protein
identified in each of the ascitic MA supernatants, out of the
30–60 total proteins identified, but not in buffy coat MO/
MA supernatant it is reasonable to consider a possible role
for this protein in the biology of EOC.
Macrophages release a number of inflammatory cyto-
kines and chemokines. A speculated role of secreted 14-3-3
zeta in the tumor microenvironment might be either to
enhance or inhibit tumor growth and proliferation. The data
presented here represent the first description of the isola-
tion and expression of this protein in cells from the EOC
tumor environment. We also demonstrate for the first time
that 14-3-3 zeta is secreted by ascitic MO/MA from EOC
patients and present in malignant ascites of EOC patients.
A functional role for 14-3-3 zeta as a secreted protein has
not been elucidated; however 14-3-3 zeta has known
diverse activities as an intracellular adaptor protein. We
therefore conducted an experiment to determine whether
the protein could be taken up by tumor cells that do not
usually express easily detectable levels. In co-incubation
experiments, utilizing 2 established ovarian tumor cell
lines that do not express 14-3-3 zeta, we demonstrated that
FLAG-tagged 14-3-3 zeta was indeed taken-up by EOC
cells. The precise structure of 14-3-3 zeta isolated from
ascites of EOC patients is unknown. However, the migra-
tion observed in SDS-PAGE during immunoblot analysis
indicated that secreted form of the 14-3-3 zeta is intact. It is
unproven that 14-3-3 zeta has a paracrine role in EOC.
However, since the 14-3-3 zeta is an adaptor protein that is
produced and secreted by tumor associated MO/MA at the
tumor site, it is possible to speculate a possible role in
regulating the inflammatory pathways of the EOC micro-
environment. Since activated MO/MA are increased in the
peritoneum of advanced ovarian cancer patients, it is also
possible that 14-3-3 zeta might serve as a biomarker of
tumor associated inflammation independent of its possible
functions.
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